ArticleJournal of industrial microbiology & biotechnology2016
Synthetic pathway optimization for improved 1,2,4-butanetriol production.
Article in Journal of industrial microbiology & biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 43 citations in OpenAlex.
- Cellulose saccharification to alleviate CCR of xylose for enhanced 1, 2, 4-butanetriol production.Biodesign research · 2026Article
- Enzyme and cofactor engineering to increase d-xylonate dehydratase activity for improved d-1,2,4-butanetriol production from d-xylose.Synthetic and systems biotechnology · 2025Article
- Progress in research on the biosynthesis of 1,2,4-butanetriol by engineered microbes.World journal of microbiology & biotechnology · 2024Review
- The Biosynthesis of D-1,2,4-Butanetriol From d-Arabinose With an EngineeredFrontiers in bioengineering and biotechnology · 2022Article
- Understanding D-xylonic acid accumulation: a cornerstone for better metabolic engineering approaches.Applied microbiology and biotechnology · 2021Review
- Engineering microbial pathways for production of bio-based chemicals from lignocellulosic sugars: current status and perspectives.Biotechnology for biofuels · 2020Review
- Engineering Escherichia coli to grow constitutively on D-xylose using the carbon-efficient Weimberg pathway.Microbiology (Reading, England) · 2018Article
- Computational study of Simultaneous synthesis of optically active (RS)-1,2,4-butanetriol trinitrate (BTTN).Journal of molecular modeling · 2017Article
- Engineering redox homeostasis to develop efficient alcohol-producing microbial cell factories.Microbial cell factories · 2017Review
- Reexamination of the Physiological Role of PykA in Escherichia coli Revealed that It Negatively Regulates the Intracellular ATP Levels under Anaerobic Conditions.Applied and environmental microbiology · 2017Article
- Metabolic engineering ofBioresources and bioprocessing · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1,2,4-Butanetriol (BT) is an important non-natural chemical with a variety of industrial applications. Identifying the bottlenecks for BT biosynthesis is expected to contribute to improving the efficiency of this process. In this work, we first constructed a prototype strain for BT production by assembling a four-step synthetic pathway and disrupting the competing pathways for xylose in Escherichia coli BW25113. Using this prototype strain, we conducted systematic fine-tuning of the pathway enzyme expression level to identify the potential bottlenecks and optimize the BT biosynthesis. Production conditions were also optimized by exploring the effects of temperature, pH and cell density on BT titer. BT production was increased by 4.3-fold from the prototype strain, achieved a final titer of 1.58 g/L with a yield of 7.9% after 72-h biotransformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.